Navigation Links
Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
Date:5/30/2013

WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013, the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC being held from June 1, 2013 through June 5, 2013 in Baltimore and the Endocrine Society's 95th Annual Meeting (ENDO) being held June 15, 2013 through June 18, 2013 in San Francisco.  Non-24 is a serious and rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (synchronize) their master body clock to the 24-hour day. 

Tasimelteon data at SLEEP 2013 will be presented as a late breaking abstract and the data at ENDO 2013 will be presented in a poster and oral presentation.  The data presentation schedule is as follows:

-- SLEEP 2013 Baltimore
Late Breaking Abstract #005 June 5, 2013 at 12:15 PM-1:30 PM

-- ENDO 2013 San Francisco
SUN-134 June 16, 2013 at 1:45 PM – 3:45 PM
SUN-137 June 16, 2013 at 1:45 PM – 3:45 PM

About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. Non-24 affects the majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S.  Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain the master body clock in the brain with the 24-hour day-night cycle.  Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24-hours each day.  Individuals with Non-2
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
2. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
3. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
4. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
5. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
7. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
8. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
9. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
10. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
11. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014  Isis Pharmaceuticals, ... webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and Highlights ... 7:30 a.m. PTWhere: www.isispharm.com How:Live on the Internet. ... are unable to participate during the live event, a ... limited time at www.isispharm.com . ABOUT ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma Corp. ... will report its second quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... DIA and the National Pharmaceutical Council (NPC) ... User,s Guide  Conference on March 14-15 at the ... will focus on the continued push for increased ... applied within health technology assessments, research planning and ...
... 2012 PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ... February 27, 2012, it completed a share exchange ... focused on developing and commercializing proprietary clinical diagnostic ... as well as companion therapeutics to prevent systemic ...
Cached Medicine Technology:DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 3PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 4
(Date:7/28/2014)... patients with one of the UK,s most common respiratory ... obstructive pulmonary disease (COPD) is the name for a ... long-term damage to the lungs. Often linked to ... all hospital admissions in the UK, with a high ... are discharged. , A team of researchers, ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and chiropractor ... investment capital through her crowd funding camping to tap ... States. , According to a statement released by Drorit ... a great window of opportunity for investors like her ... to this, Silverman looks at the 24/7 fitness concept ...
(Date:7/28/2014)... 28, 2014) -- Researchers from The University of Texas Health ... other institutions have identified a combination of pills that cures ... the drugs sofosbuvir and simeprevir, with or without ribavirin, cured ... tolerated by patients, according to the study published today in ... in the U.S. , Eric Lawitz, M.D., clinical professor ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market report ... America with analysis and forecast of revenue. This market is ... $812.7 million by 2018, at a CAGR of 7.1% from ... North America Carotenoids & Antioxidants Market report to get an ... glimpse of the segmentation in the market, and is supported ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Oneida ... and an incredible field of accompanying PGA TOUR players ... and golf analyst Notah Begay III for the seventh ... Turning Stone Resort Casino ’s Atunyote® Golf Club ... will include Woods, Jason Dufner, Jimmy Walker, Jonas Blixt, ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5
... DALLAS and PLANO, Texas, March 1 Skin damage. If,you ... about you -- about,your time as a smoker (lip lines), ... age spots), or perhaps you,re,seeing a little more of Mom ... Yes, part of what you,re seeing is normal skin aging, ...
... The California,Academy of Physician Assistants (CAPA) announced that physician ... Speaker of the,California State Assembly. Bass, a member of ... former faculty member at the,University of Southern California School ... Assembly in 2004., As a physician assistant (PA), ...
... 29, 2008 A new study led by researchers at ... that can enhance the function of a protein that is ... protein, called AML1, plays a critical role in the development ... and immune cells. The findings are published in the March ...
... to be unveiled at the 2008 Orthopedic Research ... Society meeting in San Francisco, ... collaboration with RUSH University in Chicago, announces significant,findings that wear ... accelerated aging. The study, "The Effect,of Accelerated Aging on the ...
... Separate Medical ... Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, Inc. (NYSE: ... a cash tender offer to purchase any and all of ... of which $250,million in aggregate principal amount was outstanding as ...
... small striped fish is helping scientists understand what makes people ... this case, its not the fishs ears that are of ... of the journal PLoS Genetics, researchers at the University of ... zebrafishs lateral linethe faint line running down each side of ...
Cached Medicine News:Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 2Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 3Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 4Health News:Physician Assistant Karen Bass Elected Speaker Elect of California State Assembly 2Health News:Novel mechanism found that may boost impaired function of leukemia protein 2Health News:Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 3
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: